Marshall Henry, Berry Ella C, Torres Santiago Diaz, Mullany Sean, Schmidt Joshua, Thomson Daniel, Nguyen Thi Thi, Knight Lachlan Sw, Hollitt Georgina, Qassim Ayub, Kolovos Antonia, Ridge Bronwyn, Schulz Angela, Lake Stewart, Mills Richard A, Agar Ashish, Galanopoulos Anna, Landers John, Healey Paul R, Graham Stuart L, Hewitt Alex W, Casson Robert J, MacGregor Stuart, Siggs Owen M, Craig Jamie E
From Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, Australia (H.M, E.C.B, S.M, J.S, D.T, T.T.N, L.S.W.K, G.H, A.Q, A.K, B.R, S.L, R.A.M, J.L, O.M.S, J.E.C).
From Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, Australia (H.M, E.C.B, S.M, J.S, D.T, T.T.N, L.S.W.K, G.H, A.Q, A.K, B.R, S.L, R.A.M, J.L, O.M.S, J.E.C).
Am J Ophthalmol. 2023 Jan;245:126-133. doi: 10.1016/j.ajo.2022.08.006. Epub 2022 Aug 13.
To evaluate the relationship between body mass index (BMI) and glaucoma progression.
Multicohort observational study.
This study combined a retrospective longitudinal analysis of suspect and early manifest primary open angle glaucoma cases from the Progression Risk of Glaucoma: RElevant SNPs with Significant Association (PROGRESSA) study with 2 replication cohorts from the UK Biobank and the Canadian Longitudinal Study of Ageing (CLSA). In the PROGRESSA study, multivariate analysis correlated BMI with longitudinal visual field progression in 471 participants. The BMI was then associated with glaucoma diagnosis and cross-sectional vertical cup-disc ratio (VCDR) measurements in the UK Biobank, and finally prospectively associated with longitudinal change in VCDR in the CLSA study.
In the PROGRESSA study, a lower BMI conferred a faster rate of visual field progression (mean duration of monitoring (5.28 ± 1.80 years (10.6 ± 3.59 visits) (β 0.04 dB/year/SD95% CI [0.005, 0.069]; P = .013). In the UK Biobank, a 1 standard deviation lower BMI was associated with a worse cross-sectional VCDR (β -0.048/SD 95% CI [-0.056, 0.96]; P < .001) and a 10% greater likelihood of glaucoma diagnosis, as per specialist grading of retinal fundus imaging (OR 0.90 95% CI [0.84, 0.98]; P = .011). Similarly, a lower BMI was associated with a greater risk of glaucoma diagnosis as per International Classification of Disease data (OR 0.94/SD; 95% CI [0.91, 0.98]; P = .002). Body mass index was also positively correlated with intraocular pressure (β 0.11/SD; 95% CI [0.06, 0.15]; P < .001). Finally, a lower BMI was then associated with greater VCDR change in the CLSA (β -0.007/SD; 95% CI [-0.01, -0.001]; P = .023).
Body mass index correlated with longitudinal and cross-sectional glaucomatous outcomes. This supports previous work illustrating a correlation between BMI and glaucoma.
评估体重指数(BMI)与青光眼进展之间的关系。
多队列观察性研究。
本研究将青光眼进展风险:具有显著关联的相关单核苷酸多态性(PROGRESSA)研究中可疑和早期显性原发性开角型青光眼病例的回顾性纵向分析与来自英国生物银行和加拿大老龄化纵向研究(CLSA)的2个复制队列相结合。在PROGRESSA研究中,多变量分析将471名参与者的BMI与纵向视野进展相关联。然后在英国生物银行中,将BMI与青光眼诊断及横断面垂直杯盘比(VCDR)测量相关联,最后在CLSA研究中前瞻性地将其与VCDR的纵向变化相关联。
在PROGRESSA研究中,较低的BMI导致视野进展速度更快(平均监测持续时间(5.28±1.80年(10.6±3.59次就诊)(β0.04 dB/年/标准差95%可信区间[0.005, 0.069];P = 0.013)。在英国生物银行中,BMI每降低1个标准差与更差的横断面VCDR相关(β -0.048/标准差95%可信区间[-0.056, 0.96];P < 0.001),并且根据视网膜眼底成像的专家分级,青光眼诊断的可能性高10%(比值比0.90 95%可信区间[0.84, 0.98];P = 0.011)。同样,根据国际疾病分类数据,较低的BMI与青光眼诊断风险增加相关(比值比0.94/标准差;95%可信区间[0.91, 0.98];P = 0.002)。体重指数也与眼压呈正相关(β0.11/标准差;95%可信区间[0.06, 0.15];P < 0.001)。最后,在CLSA中,较低的BMI与更大的VCDR变化相关(β -0.007/标准差;95%可信区间[-0.01, -0.001];P = 0.023)。
体重指数与纵向和横断面青光眼结局相关。这支持了先前关于BMI与青光眼之间相关性的研究工作。